(Reuters) -Pfizer Inc. stuck with its annual sales projections for COVID-19 antiviral Pill Paxlovid, and its vaccines on Tuesday despite tepid market demand.

It said that it expected $22 Billion in Paxlovid Sales this year. The company also reiterated its prediction of $32 Billion in Paxlovid sales this year, which it developed together with BioNTech.

A number of drug companies responded to U.S. Securities and Exchange Commission’s request and adjusted their forecasts so that they included milestone payments and acquisitions.

According to company, it expects full year adjusted profit between $6.25 and $6.45 per share. This is lower than its previous forecast of $6.35 to 6.55. The impact of these expenses was a major reason for the decrease in revenue.